A new oral lipid lowering treatment as add-on to improve LDL-C control in your (very) high risk CV patients

10/06/2021 19:30-21:00 Cardiology

National webinar on Bempedoic acid, a new oral lipid lowering treatment as add-on to improve LDL-C control in your (very) high risk CV patients with Prof. dr. François Mach and Prof. dr. Kausik Ray. BEM/21/0205 Date of last revision April 2021

Register
Share:

Description

National webinar on Bempedoic acid, a new oral lipid lowering treatment as add-on to improve LDL-C control in your (very) high risk CV patients.

Prof dr François Mach – What do the ESC/EAS guidelines about the management of dyslipidemias say?

Director of the cardiology basic science laboratory at the Faculty of Medicine University of Geneva, Switzerland
National CVD Prevention Coordinator for Switzerland
First author of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

Prof dr Kausik Ray – How to use the clinical evidence of bempedoic acid in your daily clinical practice?

FESC, Professor of Public Health. Director of the Imperial Centre for CVD Prevention.
Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials Imperial College London and Consultant Cardiologist. President European Atherosclerosis Society.

 

Reviews

There are no reviews yet.

Be the first to review “A new oral lipid lowering treatment as add-on to improve LDL-C control in your (very) high risk CV patients”

Your E-mailadres will not be published. Required fields are marked *